An open study of triiodothyronine augmentation of selective serotonin
reuptake inhibitors in treatment-resistant major depressive disorder

Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH,
Papakostas GI, Ryan JL, Alpert JE, Fava M.
From the Depression Clinical and Research Program,
Massachusetts General Hospital,
Harvard Medical School, Boston.
J Clin Psychiatry. 2005 Aug;66(8):1038-42.


OBJECTIVE: In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment. METHOD: Twenty subjects who met DSM-IV criteria for MDD (mean +/- SD age = 44.3 +/- 10.3 years; 55% [N = 11] women) and had failed to respond to a course of treatment of at least 8 weeks with an SSRI antidepressant were enrolled in a 4-week open-label augmentation treatment with T(3) 50 mug/day. Atypical and melancholic sub-types of MDD were diagnosed using Structured Clinical Interview for DSM-IV Axis I Disorders criteria. We administered the 17-item Hamilton Rating Scale for Depression (HAM-D-17) 4 times during the study (which was conducted between 2001 and 2003). RESULTS: During T(3) augmentation, the severity of depression decreased from an initial mean +/- SD HAM-D-17 score of 20.5 +/- 3.6 to a final HAM-D-17 score of 14.0 +/- 7.1 (p < .001). Seven subjects (35.0%) were treatment responders (HAM-D-17 reduction >/= 50%), and 6 subjects (30.0%) achieved clinical remission (final HAM-D-17
The thyroid axis
Thryoid supplementation
Thyroxine (T4): structure
Hypothyroidism and depression
The thyroid axis and depression
Triiodothyronine (T3) and major depression
Thyroid hormone, mood modulation and the brain

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family